Altheia Science
Italy - MilanBiotechnology
Focus: Altheia Science is a Milan-based biotech company specializing in cell and gene therapy approaches for autoimmune disorders, particularly Type 1 Diabetes. The company operates as a pre-revenue stage biotech with a focused pipeline in immunology and gene therapy.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Altheia Science
AI assessmentNot HiringNo open roles listed right now. Follow Altheia Science to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Autologous CD34+ cell enriched population containing HSPCs transduced with LVV encoding hPD-L1
Diabetes, Type 1Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA
Diabetes, Type IClinical Trials (1)
Help build intelligence for Altheia Science
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.